Bone Biologics Corp Warrants
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's lead medical device NELL-1/DBM, an osteopromotive recombinant protein that provides target-specific control over bone regeneration. It also develops NELL-1/DBM fusion device used in lumbar spinal fusion. The company's NELL-1 platform technology use… Read more
Bone Biologics Corp Warrants (BBLGW) - Total Assets
Latest total assets as of June 2025: $7.00 Million USD
Based on the latest financial reports, Bone Biologics Corp Warrants (BBLGW) holds total assets worth $7.00 Million USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Bone Biologics Corp Warrants - Total Assets Trend (2009–2024)
This chart illustrates how Bone Biologics Corp Warrants’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Bone Biologics Corp Warrants - Asset Composition Analysis
Current Asset Composition (December 2024)
Bone Biologics Corp Warrants's total assets of $7.00 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 86.1% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2009–2024)
This chart illustrates how Bone Biologics Corp Warrants's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bone Biologics Corp Warrants's current assets represent 100.0% of total assets in 2024, an increase from 0.0% in 2009.
- Cash Position: Cash and equivalents constituted 86.1% of total assets in 2024, up from 0.0% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2009.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Bone Biologics Corp Warrants Competitors by Total Assets
Key competitors of Bone Biologics Corp Warrants based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
Bone Biologics Corp Warrants - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Bone Biologics Corp Warrants generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Bone Biologics Corp Warrants is currently not profitable relative to its asset base.
Bone Biologics Corp Warrants - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 17.24 | 11.22 | 0.00 |
| Quick Ratio | 17.24 | 11.22 | 0.00 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $6.60 Million | $ 2.91 Million | $ -13.24 Million |
Bone Biologics Corp Warrants - Advanced Valuation Insights
This section examines the relationship between Bone Biologics Corp Warrants's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 2.09 |
| Asset Growth Rate (YoY) | 3.3% |
| Total Assets | $3.86 Million |
| Market Capitalization | $8.06 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Bone Biologics Corp Warrants's assets at a significant premium ( 2.09x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Bone Biologics Corp Warrants's assets grew by 3.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Bone Biologics Corp Warrants (2009–2024)
The table below shows the annual total assets of Bone Biologics Corp Warrants from 2009 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $3.86 Million | +3.31% |
| 2023-12-31 | $3.74 Million | -56.00% |
| 2022-12-31 | $8.50 Million | +27.26% |
| 2021-12-31 | $6.68 Million | -- |
| 2020-12-31 | $0.00 | -- |
| 2019-12-31 | $30.83K | -97.04% |
| 2018-12-31 | $1.04 Million | +30.80% |
| 2017-12-31 | $795.66K | -18.23% |
| 2016-12-31 | $973.09K | -53.22% |
| 2015-12-31 | $2.08 Million | -45.56% |
| 2014-12-31 | $3.82 Million | +4277.06% |
| 2013-12-31 | $87.31K | +3683655.27% |
| 2012-12-31 | $2.37 | -100.01% |
| 2009-12-31 | $-39.77K | -- |